Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission

被引：15

作者：

Giuliano, M

Palmisano, L

Galluzzo, CM

Amici, R

Germinario, E

Okong, P

Kituuka, P

Mmirro, F

Magoni, M

Vella, S

机构：

[1] Ist Super Sanita, Virol Lab, I-00161 Rome, Italy

[2] St Francis Nsambya Hosp, Kampala, Uganda

[3] Mulago Hosp, Kampala, Uganda

来源：

AIDS | 2003年 / 17卷 / 10期

关键词：

D O I：

10.1097/00002030-200307040-00022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Two zidovudine/lamivudine regimens for the prevention of HIV perinatal transmission were studied for the selection of resistance mutations. The M184V mutation was detected one week after delivery in six out of fifty women (12%) who received the regimen prepartum, intrapartum and postpartum, and was no longer present 3 months later. No nucleoside reverse transcriptase inhibitor resistance-associated mutations were detected in 50 women who received zidovudine/lamivudine intrapartum and postpartum only. No association with the risk of perinatal transmission was found.

引用

页码：1570 / 1572

页数：3

共 50 条

[41] Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: The impact of social network factors, side effects, and perceived treatment efficacy
Demas, PA
Thea, DM
Weedon, J
McWayne, J
Bamjl, M
Lambert, G
Schoenbaum, EE
WOMEN & HEALTH, 2005, 42 (01) : 99 - 115
[42] HIV type 1 zidovudine (ZDV) resistance in blood and uterine cervical secretions of pregnant women
Frenkel, Lisa M.
McKernan, Jennifer
Dinh, Phil V.
Goldman, Deborah
Hitti, Jane
Watts, D. Heather
Cooper, Ellen R.
Dragavon, Joan
Coombs, Robert W.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (09) : 870 - 873
[43] Zidovudine resistance phenotype and risk of perinatal HIV-1 transmission in zidovudine monotherapy-treated mothers with moderately advanced disease
Bauer, GR
Welles, SL
Colgrove, RR
Pitt, J
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 (03) : 312 - 319
[44] Modulation of K65R Selection by Zidovudine Inclusion: Analysis of HIV Resistance Selection in Subjects with Virologic Failure Receiving Once-Daily Abacavir/Lamivudine/Zidovudine and Tenofovir DF (Study COL40263)
Ross, Lisa
Elion, Richard
Lanier, Randall
Dejesus, Edwin
Cohen, Calvin
Redfield, Robert R.
Gathe, Joseph C.
Hsu, Ricky K.
Yau, Linda
Paulsen, D.
Ha, Belinda
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2009, 25 (07) : 665 - 672
[45] Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants
Mofenson, LM
Munderi, P
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 30 (02) : 200 - 215
[46] Is There a Higher Risk of Mother-to-child Transmission of HIV Among Pregnant Women With Perinatal HIV Infection?
Goodenough, Christopher J.
Patel, Kunjal
Van Dyke, Russell B.
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (12) : 1267 - 1270
[47] A RISK-BENEFIT ASSESSMENT OF ZIDOVUDINE IN THE PREVENTION OF PERINATAL HIV TRANSMISSION
NEWELL, ML
GIBB, DM
DRUG SAFETY, 1995, 12 (04) : 274 - 282
[48] Short Duration of Lamivudine for Prevention of HBV Transmission in Pregnancy: Lack of Potency and Selection of Resistance Mutations
Yuen, Lilly
Ayres, Anna
Jackson, Kathy
Bayliss, Julianne
Manoharan, Suthaharan
Glass, Anne L.
Maley, Michael
Bowden, Scott
Luciani, Fabio
Levy, Miriam
Locarnini, Stephen
HEPATOLOGY, 2013, 58 : 699A - 699A
[49] Prevention of perinatal transmission of zidovudine- and nevirapine-resistant HIV
Cha, Agnes
Elsamadisi, Pansy
Su, Christy Peggy
Phipps, Emmet
Birnbaum, Jeffrey M.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (07) : 451 - 455
[50] Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV
Simonds, RJ
Steketee, R
Nesheim, S
Matheson, P
Palumbo, P
Alger, L
Abrams, EJ
Orloff, S
Lindsay, M
Bardeguez, AD
Vink, P
Byers, R
Rogers, M
AIDS, 1998, 12 (03) : 301 - 308

← 1 2 3 4 5 →